July 31, 2007 – Bridge Pharmaceuticals has hired a new CEO, D. Thomas Oakley, replacing Dr. Glenn Rice, who founded Bridge. The company also moved new people into the CFO and Chief Scientific Officer posts. Bridge, a pre-clinical contract research organization, has been busy. In recent months, it brought its B funding round up to $57 million, purchased a pre-clinical lab from Gene Logic, moved its corporate headquarters to Maryland, and instituted a visiting scholars program for its employees that allows them to cross-train in China or the US. More details...
